Drug discovery enters a new era with multi-target intervention strategy

Xiao-ying Tian; Liang Liu

doi:10.1007/s11655-011-0900-2

Your Location：

Home >

Browse articles >

Drug discovery enters a new era with multi-target intervention strategy

Updated：2021-08-27

- Drug discovery enters a new era with multi-target intervention strategy
- Chinese Journal of Integrative Medicine Vol. 18, Issue 7, Pages: 539-542(2012)
- Affiliations：
  
  1. Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University,Hong Kong SAR,China
  2. State Key Laboratory for Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macau,China
- Author bio：
- Funds：
  
  Supported by Hong Kong Baptist University (RC/08-09/GEN-043)
- DOI：10.1007/s11655-011-0900-2
  CLC：
- Published：2012，
  
  Published Online：11 April 2012，
Scan for full text
Tian, Xy., Liu, L. Drug discovery enters a new era with multi-target intervention strategy., Chin. J. Integr. Med. 18, 539–542 (2012). https://doi.org/10.1007/s11655-011-0900-2

Xiao-ying Tian, Liang Liu. Drug discovery enters a new era with multi-target intervention strategy. [J]. Chinese Journal of Integrative Medicine 18(7):539-542(2012)
Tian, Xy., Liu, L. Drug discovery enters a new era with multi-target intervention strategy., Chin. J. Integr. Med. 18, 539–542 (2012). https://doi.org/10.1007/s11655-011-0900-2 DOI：

Xiao-ying Tian, Liang Liu. Drug discovery enters a new era with multi-target intervention strategy. [J]. Chinese Journal of Integrative Medicine 18(7):539-542(2012) DOI： 10.1007/s11655-011-0900-2.

摘要

In the past century

as medical research has become increasingly precise

it has become clear that the incidence and progression of many diseases involve multiple factors and pathologies; this is particularly true for the degenerative and metabolic diseases facing industrialized societies. At the same time

it becomes increasingly clear that single-target action drugs cannot effectively treat these diseases. Researchers are looking toward the chemical industry as well as traditional herbal medicines to find multi-target interventions. Thus

a new era in drug discovery has begun. Specifically

three approaches have proven effective in seeking multi-target drugs. These are: (1) designing drugs with multiple components; (2) discovering drugs through the study of synergistic compound-compound interactions in medicinal herbs or among chemical drugs and herbal components; and (3) developing drugs to tackle complex multi-component diseases. The authors conclude that there is an increasing need for multi-component remedies to treat the complex chronic diseases afflicting modern populations. Given this situation and the growing body of evidence that these new approaches are effective

multi-target intervention appears to have great potential for discovering

designing

and developing effective new drugs for today’s diseases.

Abstract

In the past century

as medical research has become increasingly precise

a new era in drug discovery has begun. Specifically

multi-target intervention appears to have great potential for discovering

designing

and developing effective new drugs for today’s diseases.

关键词

multi-target interventioncompound-compound interactionherb-drug interactionsynergymulti-component remedy

Keywords

multi-target interventioncompound-compound interactionherb-drug interactionsynergymulti-component remedy

references

Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005;4:71–78.

Zhang QY, Mao JH, Liu P, Huang QH, Lu J, Xie YY, et al. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci USA 2009;106:3378–3383.

Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 2000;97:1433–1437.

Liu ZQ, Zhou H, Liu L, Jiang ZH, Wong YF, Xie Y, et al. Influence of co-administrated sinomenine on pharmacokinetic fate of paeoniflorin in unrestrained conscious rats. J Ethnopharmacol 2005;99:61–67.

Liu ZQ, Jiang ZH, Liu L, Hu M. Mechanisms responsible for poor oral bioavailability of paeoniflorin: role of intestinal disposition and interactions with sinomenine. Pharm Res 2006;23:2768–2780.

Chan K, Liu ZQ, Jiang ZH, Zhou H, Wong YF, Xu HX, et al. The effects of sinomenine on intestinal absorption of paeoniflorin by the everted rat gut sac model. J Ethnopharmacol 2006;103:425–432.

Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552–556.

Land H, Chen AC, Morgenstern JP, Parada LF, Weinberg RA. Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol 1986;6:1917–1925.

Dotto GP, Parada LF, Weinberg RA. Specific growth response of ras-transformed embryo fibroblasts to tumour promoters. Nature 1985;318:472–475.

Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596–602.

Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy—from TCM theory to mechanistic insights. Planta Med 2010;76:1118–1131.

Macián F, García-Cózar F, Im SH, Horton HF, Byrne MC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 200 2002;109:719–731.

Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L. Matrine induces cell anergy in human Jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated T-cells signaling with concomitant up-regulation of anergy-associated genes expression. Biol Pharm Bull 2010;33:40–46.

Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L. Pseudolaric acid B suppresses T lymphocyte activation through inhibition of NF-kappaB signaling pathway and p38 phosphorylation. J Cell Biochem 2009;108:87–95.

FULL TEXT LINK

More>

Views

886

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Understanding interactions between Chinese medicines and pharmaceutical drugs in integrative healthcare

Potential herb-drug interaction in the prevention of cardiovascular diseases during integrated traditional and western medicine treatment

Alterations of Gefitinib Pharmacokinetics by Co-administration of Herbal Medications in Rats

Related Author

No data

Related Institution

The National Institute of Complementary Medicine, University of Western Sydney

Faculty of Pharmacy, The University of Sydney

Cardiovascular Department, Shanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

College of Pharmacy, Catholic University of Daegu, Gyeongbuk, Republic of Korea

School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰